Two years after FDA refused to review Roche/Genentech Inc.’s T-DM1 for accelerated approval, the company has resubmitted the application, but this time with a statistically significant overall survival advantage in hand – FDA’s gold standard for oncology approvals.
The company announced Aug. 27 that it had submitted a BLA to FDA for the antibody drug conjugate trastuzumab emtansine, a combination of the monoclonal antibody Herceptin (trastuzumab) with the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?